The Impact Of The Coronavirus (Covid-19) Pandemic Is Expected To Limit The Growth Of The Global Antibody Drug Conjugates Market
ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific for surface antigens found on specific tumour cells with highly effective anticancer agents linked by chemical linkers. Antibody-drug conjugates, in a nutshell, deliver "deactivated" cytotoxins to cancer cells. Once inside the tumour cell – internalisation – the cytotoxin re-establishes its full cytotoxic – cancer-killing – activity. As a result, cell death is rapid. There are thousands of cellular toxins derived from natural sources or chemically synthesised, but only a few of them are suitable as components in an antibody-drug conjugate (ADCs). Early ADCs were developed with clinically approved chemotherapeutic drugs like doxorubicin and methotrexate.
As a result of cancer screening discontinuation and postponed hospital visits, the impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global Antibody Drug Conjugates Market. According to a July 2021 article published in The Lancet Oncology, an ambidirectional cohort study was conducted at 41 cancer centres in India that were members of the National Cancer Grid of India to compare oncology service provision between March 1, 2020 and May 31, 2020, with the same time period in 2019. The findings of the cohort study revealed that the COVID-19 pandemic has a significant impact on cancer care. All aspects of care were reduced during the pandemic, including screening, diagnosis, treatment, palliative care, and follow-up.
Increased cancer prevalence worldwide, unhealthy urban lifestyles, and increased consumption of tobacco and alcohol across geographies are major cancer risk factors. "The number of people living beyond cancer diagnosis is expected to reach approximately 19 million by 2024," according to the National Cancer Institute. During the study period, the Antibody Drug Conjugates Market is expected to be driven by an increase in demand for cost-effective and high-quality cancer treatment. The rising prevalence of breast cancer is expected to drive the global antibody drug conjugates market forward. According to the Centers for Disease Control and Prevention (CDC), the United States reported 254,744 new cases of breast cancer in women in 2018, with 42,465 women dying from the disease. Furthermore, in 2018, 127 new cases of breast cancer were diagnosed in 100,000 women, and 20 women died as a result of the disease.
Comments
Post a Comment